DHDP announces new Executive Committee
May 6, 2021
Vancouver, BC -- The Digital Health & Discovery Platform is pleased to announce the 16 members of its Executive Committee, made up of Canadian thought leaders and influencers from across the healthcare and AI communities.
This pan-Canadian representation of key opinion leaders will be vital to the success of the DHDP, with the members providing oversight on issues such as governance, sustainability, stakeholder accountability and risk management.
“From the start, we had a vision of bringing the power of the Canadian ecosystem to accelerate innovative medical breakthroughs using AI to improve patient outcomes. We are now beginning a true pan-Canadian collaboration that includes the 16 thought leaders who make up the new DHDP Executive Committee representing academic, AI, medical, private and public sectors. They are all influential leaders in their respective fields and will be key in rallying the country to end cancer and neurodegenerative diseases,” said Alexandre Le Bouthillier, Imagia Co-founder & Chief Corporate Officer.
“The DHDP presents a unique opportunity for us to bridge the gap between Canada’s public health system, our world-class research community and our innovative private sector to collaborate to create solutions that benefit Canadians with cancer and other diseases,” said Dr. Victor Ling, TFRI President and Scientific Director. “Our Executive Committee reflects these sectors, providing us with a diverse set of voices which will help us find new ways to intelligently apply Big Data and Artificial Intelligence to provide patients with better outcomes using precision medicine.”
“The DHDP is fortunate to have such an engaged group of high calibre leaders forming the Executive Committee. I look forward to working with each of them as we bring our community together to realize the DHDP’s vision of making precision medicine and personalized clinical care in cancer and neurodegenerative disease accessible to all Canadians,” said Bryce Pickard, Executive Director of the DHDP.
Presenting our members, as shown in the photo above:
- First row (left to right)
- Rodney Ouellette, President and scientific director, Atlantic Cancer Research Institute
- Valérie Pisano, CEO, Mila
- Laszlo Radvanyi, CEO, OICR
- Nicole Mittmann, CSO & VP Evidence Standards, CADTH
- Second row (left to right)
- Nadine Beauger, CEO, IRICOR
- Kirk Rockwell, COO, Amii
- Guillaume Bourque, Associate Professor, Dept. of Human Genetics, McGill
- Fabrice Brunet, CEO, CHUM
- Third row (left to right)
- Guy Rouleau, Director, The Neuro
- Benjamin Haibe-Kains, Senior scientist, UHN
- Diane Côté, CEO, MEDTEQ
- Andrew Casey, President & CEO, BIOTECanada
- Fourth row (left to right)
- Colette Kaminsky, Associate Assistant Deputy Minister, ISED (Observer)
- David McFarlane, Vice President Global Alliances, Kinova
- François Benard, Vice-President, Research, BC Cancer Care
- Roxana Sultan, Vice-President, Health, Vector Institute
About the DHDP
The DHDP takes a pan-Canadian approach, leveraging a collaborative network of key experts and partners, to deliver a cutting-edge technological infrastructure coupled with a world-leading policy framework. The DHDP creates a ‘network effect’ to accelerate innovation and commercialize new products and services that contribute to Canada’s knowledge economy. Ultimately the DHDP will improve health outcomes for Canadians through the advancement of precision medicine.
Imagia, an AI healthcare company, develops digital medical innovations that improve the health of cancer patients and those afflicted with other high-burden diseases. Through its collaborative ecosystem, Imagia EVIDENSTM enables hospitals, medical device manufacturers, pharmaceutical companies, and diagnostic companies around the world to access and utilize healthcare data while preserving data privacy. Headquartered in Montreal, Imagia’s mission is to unlock the potential of data across all organizations to achieve collaborative, medical breakthroughs. imagia.com
About the Terry Fox Research Institute
The Terry Fox Research Institute (TFRI), established in 2007, invests in world-class, collaborative cancer research teams and partnerships. Together with its research and funding partners, TFRI is working to inspire the transformation of cancer research in this country by bringing together leading cancer research and treatment organizations in Canada and empowering them under the framework of the Marathon of Hope Cancer Centres Network. www.tfri.ca
For further information: For TFRI: Kelly Curwin, email@example.com, cell:778-237-8158, office: 604-675-8223; For Imagia: Shelley Epstein, firstname.lastname@example.org, 514-451-6343; For DHDP: Bryce Pickard, email@example.com, firstname.lastname@example.org